Status:
COMPLETED
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Lead Sponsor:
Seagen Inc.
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Eligibility Criteria
Inclusion
- Diagnosis of DLBCL.
- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.
- Progression or relapse since most recent therapy.
- At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.
Exclusion
- Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma.
- Primary refractory disease.
- Received an allogenic stem cell transplant.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00435916
Start Date
December 1 2006
End Date
January 1 2009
Last Update
January 7 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Mayo Clinic-Arizona
Scottsdale, Arizona, United States, 85259
3
University of California Los Angeles
Los Angeles, California, United States, 90095
4
Stanford University Medical Center
Palo Alto, California, United States, 94305